German chemicals giant BASF is making another attempt to acquire its smaller rival Evonik, but the target has already turned down an offer worth more than €11 billion. According to people familiar with the matter, Evonik's leadership is signaling that a higher price alone won't be enough to get a deal done.
BASF first approached Evonik in September, as reported by Reuters. Since then, Evonik's management has been telling staff that it sees strong prospects as an independent company. Two people close to Evonik said any takeover would need a clear industrial rationale—in plain English, a convincing plan for how the two businesses would fit together and operate more efficiently as one entity.
What's on the table
The offer, which BASF has sweetened to more than €11 billion, values Evonik at roughly €26 to €28 per share, according to Handelsblatt, a German business newspaper. That price range, cited by finance-industry sources, could potentially break the deadlock. But BASF is also trying to build support beyond the boardroom.
Reuters sources said BASF has written to the state of North Rhine-Westphalia, where Evonik is based, and to Evonik's largest shareholder, RAG-Stiftung. In those letters, BASF floated commitments on plants, jobs, and training. This highlights that in big German industrial deals, the "package" can include political and workforce promises, not just cash.
Why the industrial rationale matters
For investors, the €26 to €28 per-share zone is about more than the headline bid. Those side promises can change the economics of a merger. If BASF pledges to keep certain sites open, protect jobs, or fund training, it can limit how much the combined company can cut costs or reorganize later. Those cost savings—often called "synergies"—are usually how an acquirer justifies paying a premium.
So the real hurdle isn't only whether BASF can inch closer to the €26 to €28 per-share range; it's whether it can still show enough net savings after any plant and workforce commitments to make the deal add up. That's why takeover odds may swing as much on BASF's industrial plan as on its next price tag.
What it means for investors
For everyday investors, this deal is a reminder that mergers and acquisitions aren't just about the price per share. The structure of the deal—including any promises made to governments or unions—can affect how much value is actually created for shareholders of both companies.
If BASF succeeds, Evonik shareholders would receive a premium for their shares, but the long-term benefits would depend on how well the combined company executes. If the deal falls through, Evonik shares might drop back to pre-offer levels, and BASF would avoid the risks of a complex integration.
Investors should also watch how BASF finances the acquisition. A deal of this size could increase BASF's debt, which might affect its credit rating and future dividend payments. On the other hand, if the synergies are real, the combined company could become more competitive in the global chemicals market.
For now, the ball is in Evonik's court. The company's management has shown it's willing to hold out for a deal that makes strategic sense, not just a bigger number. As the negotiations continue, the market will be watching for any signs of progress—or a breakdown that could send both stocks moving.
In the broader context, this deal is part of a wave of consolidation in the chemicals industry, as companies seek scale to cope with rising energy costs and global competition. For more on how such moves affect markets, see our coverage of BASF's softer approach and the renewed push to court stakeholders.


